Genome Editing Stocks List
|2019-08-22||ABEO||New 52 Week Closing Low||Bearish|
|2019-08-22||ABEO||New 52 Week Low||Weakness|
|2019-08-22||ABEO||Reversal New Lows Setup||Bearish Swing Setup|
|2019-08-22||CRSP||Fell Below 20 DMA||Bearish|
|2019-08-22||DTIL||New 52 Week Closing Low||Bearish|
|2019-08-22||DTIL||Stochastic Reached Oversold||Weakness|
|2019-08-22||EDIT||20 DMA Support||Bullish|
|2019-08-22||EDIT||Bollinger Band Squeeze||Range Contraction|
|2019-08-22||NTLA||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup|
Genome editing, or genome engineering, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly inserts genetic material into a host genome, genome editing targets the insertions to site specific locations.
In 2018, the common methods for such editing use engineered nucleases, or "molecular scissors". These nucleases create site-specific double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations ('edits').
As of 2015 four families of engineered nucleases were used: meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN), and the clustered regularly interspaced short palindromic repeats (CRISPR/Cas9) system. Nine genome editors were available as of 2017.Genome editing with engineered nucleases, i.e. all three major classes of these enzymes—zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs) and engineered meganucleases—were selected by Nature Methods as the 2011 Method of the Year. The CRISPR-Cas system was selected by Science as 2015 Breakthrough of the Year.